<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Galderma Group AG (GDERF,GALD.SW), a Swiss skincare firm, on Thursday reported sales growth for its first quarter, with improved performance in all segments.</p><p>Further, Galderma confirmed its 2026 guidance of 17 percent to 20 percent year-over-year net sales growth and a Core EBITDA margin of about 26 percent, both at constant currency.</p><p>On the Swiss Stock Exchange, shares of Galderma were gaining 5.84 percent, trading at 159.55 francs. </p><p>For the first quarter, net sales increased 30.5 percent to $1.47 billion from $1.13 billion last year. On a constant currency, net sales grew 25.5 percent. </p><p>The sales growth was driven primarily by volume and supported by positive price and mix, led by the strong ramp-up of Nemluvio and broad strength across geographies and product categories. </p><p>All segments outperformed the market with constant currency sales growth of 13.1 percent in Injectable Aesthetics, 17.0 percent in Dermatological Skincare and 71.3 percent in Therapeutic Dermatology.</p><p>On a reported basis, Injectable Aesthetics posted net sales of $648 millio, up 18.4 percent from last year. Neuromodulators sales reached $364 million, up 17.1 percent, and Fillers &amp; Biostimulators hit $284 million, up 20.1 percent.</p><p>Dermatological Skincare net sales were $441 million, up 19.3 percent from $370 million last year.</p><p>Therapeutic Dermatology reached $385 million, up 81.4 percent on a reported basis.</p><p>Nemluvio net sales were $185 million, versus $39 million a year ago.</p><p>The company's previously declared dividend of 0.35 franc per share will be payable on April 28 to holders of record on April 27. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

DRMA

<p>Galderma Group AG reported a 30.5% increase in Q1 net sales to $1.47 billion, driven by strong performance across all segments. The company confirmed its FY26 guidance of 17-20% net sales growth and a Core EBITDA margin of about 26%. Shares rose 5.84% to 159.55 francs. Notable sales growth was seen in Injectable Aesthetics (up 18.4%), Dermatological Skincare (up 19.3%), and Therapeutic Dermatology (up 81.4%). A dividend of 0.35 franc per share is set for payment on April 28.</p>

Galderma Posts Q1 Sales Growth, Confirms FY26 Outlook, Stock Up